跳转至内容
Merck
CN

D-048

Supelco

N-去甲基氯氮平标准液 CRM 溶液

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C17H17ClN4
CAS号:
分子量:
312.80
EC 号:
MDL编号:
UNSPSC代码:
41116107
NACRES:
NA.24

等级

certified reference material

质量水平

表单

liquid

特点

Snap-N-Spike®/Snap-N-Shoot®

包装

ampule of 1 mL

制造商/商品名称

Cerilliant®

浓度

1.0 mg/mL in methanol

技术

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

应用

clinical testing

包装形式

single component solution

运输

wet ice

储存温度

−20°C

SMILES字符串

Clc1ccc2Nc3ccccc3C(=Nc2c1)N4CCNCC4

InChI

1S/C17H17ClN4/c18-12-5-6-15-16(11-12)21-17(22-9-7-19-8-10-22)13-3-1-2-4-14(13)20-15/h1-6,11,19-20H,7-10H2

InChI key

JNNOSTQEZICQQP-UHFFFAOYSA-N

一般描述

N-去甲基氯氮平是氯氮平的活性代谢物,而后者是治疗精神分裂症的非典型抗精神病药物。氯氮平在美国以Clozaril和FrazaClo®商品名出售。此款Snap-N-Spike®溶液经过认证,适用于尿液药物检测、临床毒理学、法医分析以及LC-MS/MS或GC/MS法临床监测。

应用



  • 氯氮平和N-去甲基氯氮平的药代动力学分析:Mach等人(2024)进行的一项研究分析了影响氯氮平及其代谢产物N-去甲基氯氮平血清水平的临床和药理学因素,研究提供了有关精神分裂症治疗相关给药策略和代谢途径的见解(Mach et al., 2024)。


  • 氯氮平及其代谢产物的色谱分析:Hrichi等人(2024)回顾了分析抗精神病药物(包括氯氮平和N-去甲基氯氮平)的色谱方法,这些方法是用于提高药代动力学研究的准确性并增强药物监测能力(Hrichi et al., 2024)。


  • 生活方式因素对氯氮平代谢的影响:Flanagan等人(2024)的研究探讨了咖啡和巧克力的摄入对氯氮平及其代谢产物N-去甲基氯氮平血浆浓度的影响,为我们理解饮食习惯如何影响抗精神病药物水平提供了关键数据(Flanagan et al., 2024)。


法律信息

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Clozaril is a registered trademark of Sandoz, Inc.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

警示用语:

Danger

危险分类

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

靶器官

Eyes

储存分类代码

3 - Flammable liquids

WGK

WGK 1

闪点(°F)

49.5 °F - closed cup

闪点(°C)

9.7 °C - closed cup

法规信息

危险化学品

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Maria C Olianas et al.
European journal of pharmacology, 660(2-3), 341-350 (2011-04-26)
We have previously reported that N-desmethylclozapine (NDMC), a major clozapine metabolite, acts as a δ-opioid receptor agonist. Here, we show that in different cellular systems NDMC regulates protein kinase B/Akt (Akt) signaling through the activation of δ-opioid receptors. In Chinese
Kathryn K Erickson-Ridout et al.
Pharmacogenetics and genomics, 22(8), 561-576 (2012-05-09)
Clozapine (CLZ) is an FDA approved second-generation antipsychotic for refractory schizophrenia, and glucuronidation is an important pathway in its metabolism. The aim of this study was to fully characterize the CLZ glucuronidation pathway and examine whether polymorphisms in active glucuronidating
K Koda et al.
British journal of pharmacology, 162(3), 763-772 (2010-10-21)
We have previously reported that galantamine, a weak acetylcholinesterase inhibitor, improves prepulse inhibition (PPI) deficits in mice reared in social isolation. ACh receptors are involved in the underlying mechanism of PPI, but whether rearing in social isolation causes dysfunction of
Marie Humbert-Claude et al.
Psychopharmacology, 220(1), 225-241 (2011-09-14)
The basis of the unique clinical profile of the antipsychotic clozapine is not yet elucidated. Brain histamine receptors may play a role in schizophrenia and its treatment, but their involvement in the profile of clozapine remained unknown. We explored the
Zahinoor Ismail et al.
The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 20(1), 53-60 (2011-03-23)
Although clozapine is primarily used in a younger to mid-life population of patients with psychosis, there are limited data on the clinical pharmacology of clozapine later in life. The objective of this study was to assess the magnitude and variability

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门